ISM RESEARCH GROUP

Dead / Abandoned — Abandoned — no statement of use filed (as of 22 Oct 2018)

What this means for you

This application is over — abandoned 22 Oct 2018. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
86749257
Mark type
Stylized text
Filed
07 Sept 2015
Published for opposition
26 Jul 2016
Abandoned
22 Oct 2018
Attorney of record
Michael Shariff

Goods and services

  • Class 005 — Pharmaceuticals: A pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals, namely, for treatment of AIDS, infectious diseases; a pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on humans, namely, for AIDS, infectious diseases, a pharmaceutical composition featuring a pharmaceutical carrier and an isotope selective ingredient having at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100 %, wherein the selected isotopes include stable isotopes having at least one of K-39, Mg -24, Zn-64, Rb-85, Si-26 and combination thereof and all other isotopes, wherein the pharmaceutical carrier is in the form of a solution, a gel, a cream, a spray, an aerosol, a patch, nanoparticles, inorganic molecules, organic molecules, a plant, a fruit and a vegetable, the pharmaceutical composition for treating AIDS, infectious diseases
  • Class 044 — Medical, beauty and agricultural services: medical services featuring a pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals featuring a pharmaceutical carrier and an isotope selective ingredient having at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of stable isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100 % and administering a first of the stable isotopes at least prior to and after surgical removal of a solid tumor to prevent possible metastases and occurrence of secondary effects and to prevent metastasizing followed by administering a second of the stable isotopes to transform a cancer cell phenotype into a normal cell, wherein the pharmaceutical carrier and an isotope selective ingredient having at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100 %, wherein the selected isotopes include stable isotopes having at least one of K-39, Mg -24, Zn-64, Rb-85, Si-26 and combination thereof and all other isotopes, wherein the pharmaceutical carrier is in the form of a solution, a gel, a cream, a spray, an aerosol, a patch, nanoparticles, inorganic molecules, organic molecules, a plant, a fruit and a vegetable; medical testing for diagnostics purposes for diagnosis of pathology in biological objects featuring comparative analysis of light and heavy isotopes concentrations of vital chemical elements, wherein concentrations of light and heavy isotopes are compared to the ones corresponding to a natural distribution of isotopes for a given chemical element

Owner

Prosecution history

  • 22 Oct 2018 — ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
  • 22 Oct 2018 — ABANDONMENT - NO USE STATEMENT FILED
  • 22 Mar 2018 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 20 Mar 2018 — SOU EXTENSION 3 GRANTED
  • 20 Mar 2018 — SOU EXTENSION 3 FILED
  • 20 Mar 2018 — SOU TEAS EXTENSION RECEIVED
  • 22 Sept 2017 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 20 Sept 2017 — SOU EXTENSION 2 GRANTED
  • 20 Sept 2017 — SOU EXTENSION 2 FILED
  • 20 Sept 2017 — SOU TEAS EXTENSION RECEIVED
  • 18 Jul 2017 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 17 Jul 2017 — SOU EXTENSION 1 GRANTED
  • 20 Mar 2017 — SOU EXTENSION 1 FILED
  • 14 Jul 2017 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 20 Jun 2017 — NOTICE OF REVIVAL - E-MAILED

View this trademark record on Marksy